<?xml version="1.0" encoding="UTF-8"?>
<p id="Par110">Although the efficacy of the treatment of lung diseases with MSCs is not yet conclusive, its safety and promising preclinical data warrant further exploration to COVID-19â€”especially in face of the high morbidity and mortality of the current pandemic. Because of the overlapping pathology of neurological diseases stemming from a harmful inflammatory response and COVID-19-induced pulmonary, cardiovascular, and cerebrovascular disorders, MSCs may provide therapeutic benefits to COVID-19 patients where multiple organ systems are affected.</p>
